Review highlights SGLT2i, GLP-1 RAs, and nsMRAs as key therapies for slowing chronic kidney disease progression
Background
Chronic kidney disease (CKD) affects approximately 14% of US adults and 10% worldwide, driven primarily by diabetes and hypertension. These conditions lead to progressive nephron loss through disturbances in glomerular hemodynamics, filtration barrier function, and pathways of inflammation and fibrosis. Current standard-of-care, primarily renin-angiotensin-aldosterone system (RAAS) blockers, is foundational but often insufficient to halt progression, necessitating new therapeutic strategies targeting these complex mechanisms.
Study Design
This review synthesized mechanistic and clinical evidence for current and emerging therapies aimed at slowing CKD progression. It outlined a unified framework of CKD pathophysiology, summarizing disease-specific mechanisms relevant to diabetic kidney disease and hypertensive kidney disease. The authors integrated findings from various studies to evaluate the efficacy of established treatments like RAAS blockers alongside newer agents such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRAs), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as well as emerging therapies like endothelin receptor antagonists (ERAs) and angiotensin receptor-neprilysin inhibitors (ARNIs).
Results
The review established that RAAS blockers remain foundational but are now significantly complemented by several drug classes. SGLT2i were highlighted for their ability to reduce hyperfiltration, proteinuria, inflammation, and fibrosis across multiple renal compartments, leading to substantial improvements in kidney and cardiovascular outcomes. Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) were shown to effectively reduce proteinuria and mitigate inflammation and fibrosis, offering benefits beyond traditional MRAs. GLP-1 RAs demonstrated particular efficacy in diabetic kidney disease, contributing to improved glycemic control and direct renal protective effects.
These newer agents act via complementary mechanisms to reduce CKD progression, with SGLT2i and nsMRAs showing broad benefits, and GLP-1 RAs being particularly impactful in diabetic kidney disease. Emerging therapies like ERAs and ARNIs also show promise by targeting distinct pathways to further reduce proteinuria and improve renal function, suggesting a future of multi-modal combination therapy.
Key Findings
- SGLT2 inhibitors significantly reduce hyperfiltration, proteinuria, inflammation, and fibrosis in CKD.
- Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) effectively reduce proteinuria and mitigate inflammation/fibrosis.
- GLP-1 receptor agonists (GLP-1 RAs) offer significant renal protection, especially in diabetic kidney disease.
- Emerging therapies like ERAs and ARNIs show promise in further reducing proteinuria and improving renal function.
- Combination therapy leveraging complementary mechanisms is crucial for slowing CKD progression and improving outcomes.
Why It Matters
This review underscores a paradigm shift in CKD management, moving beyond sole reliance on RAAS blockers to a multi-drug approach. Clinicians and biohackers focused on kidney health should recognize the critical role of SGLT2i, nsMRAs, and GLP-1 RAs in slowing CKD progression. The practical takeaway is that combination therapy, leveraging complementary mechanisms, is now the gold standard for optimizing kidney and cardiovascular outcomes in CKD. This integrated framework provides a structured approach for combining these agents, potentially leading to more effective protocols and improved long-term prognosis for individuals with CKD. While not a new protocol, it solidifies the evidence for existing and emerging combination strategies.
chronic kidney disease
ckd
sglt2i
glp-1-ra
nsmra
renin-angiotensin-aldosterone-system